Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Sphingosine 1-phosphate Receptor Modulator [EPC]
Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults and pediatric patients 10 years and older. It works by sequestering lymphocytes in lymph nodes to reduce central nervous system inflammation.
Name
Fingolimod
Raw Name
FINGOLIMOD HYDROCHLORIDE
Category
Sphingosine 1-phosphate Receptor Modulator [EPC]
Salt Form
Hydrochloride
Drug Count
6
Variant Count
20
Last Verified
February 17, 2026
RxCUI
1012895, 1012899, 2045491, 2045493
UNII
G926EC510T, 3QN8BYN5QF
About Fingolimod
Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults and pediatric patients 10 years and older. It works by sequestering lymphocytes in lymph nodes to reduce central nervous system inflammation.
Detailed information about Fingolimod
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Fingolimod.
Fingolimod (as fingolimod hydrochloride) is a breakthrough disease-modifying therapy (DMT) and the first oral medication ever approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsing forms of multiple sclerosis (MS). It belongs to a specialized pharmacological class known as Sphingosine 1-phosphate (S1P) receptor modulators. Originally approved in 2010 under the brand name Gilenya, fingolimod represented a paradigm shift in MS management, moving treatment from frequent injections to a once-daily oral capsule. It is specifically indicated for clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in both adults and pediatric patients aged 10 years and older.
In the context of Multiple Sclerosis, the body's immune system mistakenly attacks the protective sheath (myelin) surrounding nerve fibers in the brain and spinal cord. Fingolimod acts as an immunomodulator, meaning it alters the activity of the immune system rather than completely suppressing it. By targeting specific receptors on the surface of white blood cells, fingolimod helps keep these cells 'locked' within the lymph nodes, preventing them from crossing the blood-brain barrier and causing the inflammatory damage associated with MS relapses. According to the FDA-approved labeling, fingolimod has demonstrated significant efficacy in reducing the frequency of clinical exacerbations and delaying the accumulation of physical disability compared to placebo and other active comparators like interferon beta-1a.
Fingolimod is a prodrug that undergoes phosphorylation by the enzyme sphingosine kinase 2 to form its active metabolite, fingolimod-phosphate. This active metabolite is a structural analogue of sphingosine 1-phosphate (S1P), a naturally occurring signaling lipid. S1P normally binds to five different G-protein-coupled receptors (S1P1 through S1P5) which are distributed throughout the body, including the immune system, cardiovascular system, and central nervous system (CNS).
The primary therapeutic mechanism of fingolimod involves its interaction with the S1P1 receptor located on lymphocytes (a type of white blood cell). Under normal conditions, lymphocytes follow an S1P gradient to exit the lymph nodes and enter the bloodstream. Fingolimod-phosphate binds to these S1P1 receptors with high affinity, initially stimulating them but subsequently causing the receptors to be internalized and degraded (downregulated). Without functional S1P1 receptors on their surface, lymphocytes lose their ability to respond to the S1P gradient. As a result, they remain sequestered within the peripheral lymph nodes.
Crucially, fingolimod does not destroy these cells; it simply redistributes them. By reducing the number of circulating lymphocytes (particularly pro-inflammatory Th17 cells) available to enter the CNS, fingolimod decreases the inflammatory 'attack' on myelin. Interestingly, fingolimod also crosses the blood-brain barrier and may interact with S1P receptors on glial cells (astrocytes and microglia) within the brain, potentially offering neuroprotective effects or promoting remyelination, though these mechanisms are still being extensively studied in clinical research.
The pharmacokinetics of fingolimod are characterized by slow absorption, extensive distribution, and a prolonged elimination half-life, which necessitates specific clinical management strategies.
Fingolimod is FDA-approved for the following indications:
While not FDA-approved for other conditions, some researchers have explored its use in chronic inflammatory demyelinating polyneuropathy (CIDP) and certain types of stroke, though these remain experimental and are not standard clinical practice.
Fingolimod is currently available in the following oral dosage forms:
These capsules are typically hard-gelatin shells containing the hydrochloride salt of fingolimod. Generic versions are now available in many markets, providing more cost-effective options for patients.
> Important: Only your healthcare provider can determine if Fingolimod is right for your specific condition. A thorough cardiovascular and ophthalmic screening is required before the first dose is administered.
The standard recommended dosage of fingolimod for adults with relapsing forms of multiple sclerosis is 0.5 mg taken orally once daily. Doses higher than 0.5 mg have been associated with a greater risk of adverse effects without providing additional clinical benefit. Because of the risk of bradycardia (slow heart rate) and atrioventricular (AV) block, the first dose must be administered in a setting where the patient can be monitored for at least 6 hours.
For pediatric patients (10 years of age and older), the dosage is determined by body weight:
If a pediatric patient reaches a weight of more than 40 kg while on the 0.25 mg dose, their healthcare provider will typically transition them to the 0.5 mg dose. Similar to adults, pediatric patients require a minimum 6-hour observation period after the first dose and after any dose increase.
No specific dose adjustments are required for patients with mild to severe renal impairment. However, since the metabolites are excreted renally, clinicians should monitor these patients closely for any unexpected side effects.
No dose adjustment is necessary for patients with mild or moderate hepatic impairment (Child-Pugh Class A or B). However, fingolimod should be used with extreme caution in patients with severe hepatic impairment (Child-Pugh Class C), as exposure to the drug may be increased by approximately 50%, potentially raising the risk of toxicity.
Clinical trials of fingolimod did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Fingolimod should be taken exactly as prescribed by your doctor.
If you miss a dose, do not take a double dose to make up for it. Contact your healthcare provider immediately.
In the event of an overdose, seek emergency medical attention or call the Poison Help line at 1-800-222-1222. Signs of overdose may include extreme bradycardia (very slow heart rate), chest pain, or dizziness. Because fingolimod has a very long half-life, patients who have overdosed may require prolonged observation and cardiac monitoring in a hospital setting.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop taking Fingolimod without medical guidance, as stopping the medication can lead to a severe 'rebound' worsening of MS symptoms.
According to clinical trial data, the most frequently reported side effects associated with fingolimod include:
> Warning: Stop taking Fingolimod and call your doctor immediately if you experience any of these serious symptoms.
With prolonged use of fingolimod, patients must remain vigilant about certain risks:
As of 2024, Fingolimod does not carry a traditional FDA 'Black Box Warning' in the same way some other immunosuppressants do, but it contains several 'Warnings and Precautions' that are treated with equal clinical gravity by prescribing neurologists. These include the risk of bradyarrhythmia, infections (including PML), macular edema, and the risk of severe MS worsening after discontinuation.
Report any unusual symptoms to your healthcare provider immediately. Early detection of side effects like macular edema or liver enzyme elevation often allows for management without permanent damage.
Fingolimod is a potent immunomodulator that requires careful patient selection and ongoing monitoring. Before starting treatment, patients must undergo a baseline ECG, a comprehensive eye exam, and blood tests to check liver function and complete blood counts. It is also essential to confirm immunity to Varicella Zoster Virus (chickenpox); patients without a documented history of chickenpox or vaccination should receive the Varicella vaccine at least one month before starting fingolimod.
No FDA black box warnings are currently issued for Fingolimod. However, the FDA has issued multiple Safety Communications regarding the risk of Progressive Multifocal Leukoencephalopathy (PML) and the risk of severe disability increase after stopping the drug. These warnings carry significant weight in clinical decision-making.
Standard monitoring for a patient on fingolimod includes:
Fingolimod generally does not interfere with the ability to drive or operate machinery. However, during the first 6 hours after the first dose, some patients may feel dizzy or experience heart rate changes. It is advisable to see how you react to the medication before engaging in these activities.
There is no direct contraindication between alcohol and fingolimod. However, because both alcohol and fingolimod can stress the liver, excessive alcohol consumption should be avoided to minimize the risk of hepatotoxicity.
Do not stop taking fingolimod without consulting your neurologist. Upon discontinuation, the drug remains in the system for up to 2 months. There is a risk of 'rebound' MS activity, which can be severe. Your doctor will need to monitor you closely for several months after you stop the medication.
> Important: Discuss all your medical conditions with your healthcare provider before starting Fingolimod, especially any history of heart rhythm problems, fainting, or immune system disorders.
Fingolimod should never be used with the following, as the risks significantly outweigh the benefits:
For each major interaction, the mechanism usually involves either additive pharmacodynamic effects (like slowing the heart rate) or pharmacokinetic changes (like enzyme inhibition). Management usually involves choosing alternative medications or increasing the frequency of clinical monitoring.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Keep a current list and share it with every healthcare professional you visit.
Fingolimod must NEVER be used in patients with the following conditions:
These conditions require a careful risk-benefit analysis by a specialist:
While there are no specific drugs listed for cross-sensitivity, patients who have had severe reactions to other S1P receptor modulators (like siponimod, ozanimod, or ponesimod) should be treated with extreme caution, as they share similar chemical structures and mechanisms of action.
> Important: Your healthcare provider will evaluate your complete medical history, including a full cardiac workup, before prescribing Fingolimod to ensure it is safe for you.
Fingolimod is associated with significant risks during pregnancy. Based on animal data and human reports, fingolimod may cause fetal harm, including structural abnormalities (teratogenicity). The FDA and TGA advise that women of childbearing potential must use effective contraception during treatment and for at least 2 months after stopping the medication. If a woman becomes pregnant while taking fingolimod, the drug should be discontinued immediately, and she should be counseled on the potential risks to the fetus. There is a pregnancy registry available to monitor outcomes of pregnant women exposed to fingolimod.
It is not known whether fingolimod is excreted in human milk. However, animal studies have shown that fingolimod is present in the milk of lactating rats at concentrations 2 to 3 times higher than in maternal plasma. Because of the potential for serious adverse reactions in nursing infants (including immune suppression and cardiac effects), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Fingolimod is approved for use in pediatric patients aged 10 years and older with relapsing forms of MS. The safety profile in children is generally similar to that in adults, though children may be more susceptible to certain infections and may require weight-based dosing (0.25 mg for those ≤40 kg). Long-term effects on growth and development are still being monitored, but data from the PARADIGMS trial showed fingolimod was significantly more effective than interferon beta-1a in this population.
Clinical studies did not include enough subjects aged 65 and over to determine if they respond differently. However, because elderly patients are more likely to have decreased cardiac, renal, or hepatic function, they are at a higher risk for side effects like bradycardia or liver enzyme elevation. Polypharmacy (taking multiple medications) in the elderly also increases the risk of drug-drug interactions.
In patients with renal impairment, the pharmacokinetics of fingolimod are not significantly altered. No dose adjustment is needed for patients with mild, moderate, or severe renal impairment. Fingolimod has not been specifically studied in patients with end-stage renal disease or those on dialysis, so caution is advised in these groups.
Fingolimod exposure is increased in patients with severe hepatic impairment. While no adjustment is needed for mild to moderate impairment, patients with severe (Child-Pugh C) impairment should be monitored very closely for toxicity, as their drug levels may be 50% higher than normal.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are planning a pregnancy or have underlying organ dysfunction.
Fingolimod is a sphingosine 1-phosphate (S1P) receptor modulator. It is a prodrug that is phosphorylated in vivo by sphingosine kinase 2 to its active metabolite, fingolimod-phosphate. This metabolite acts as a high-affinity agonist at S1P receptors 1, 3, 4, and 5. By binding to the S1P1 receptor on lymphocytes, it induces receptor internalization and degradation. This effectively 'blinds' the lymphocytes to the S1P gradient that normally signals them to exit the lymph nodes. Consequently, lymphocytes (specifically T and B cells) are sequestered in the lymph nodes, reducing their infiltration into the central nervous system (CNS), where they would otherwise cause inflammation and myelin destruction.
| Parameter | Value |
|---|---|
| Bioavailability | ~82% |
| Protein Binding | >99.7% (Albumin) |
| Half-life | 6 to 9 days |
| Tmax | 12 to 16 hours |
| Metabolism | Phosphorylation (Sphingosine Kinase 2); Oxidation (CYP4F2) |
| Excretion | Renal (81% as metabolites), Fecal (minor) |
Fingolimod is the first-in-class oral S1P receptor modulator. Related medications that have since been approved in this class include Siponimod (Mayzent), Ozanimod (Zeposia), and Ponesimod (Ponvory). These newer agents often target specific S1P receptor subtypes (like S1P1 and S1P5) to potentially reduce side effects related to S1P3 receptors found in the heart.
Medications containing this ingredient
Common questions about Fingolimod
Fingolimod is primarily used to treat relapsing forms of multiple sclerosis (MS) in adults and children 10 years and older. This includes clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. It works by preventing certain immune cells from entering the brain and spinal cord, thereby reducing the inflammation that causes MS symptoms and relapses. By decreasing the frequency of 'attacks,' it helps delay the progression of physical disability. It is not a cure for MS, but a disease-modifying therapy designed for long-term management.
The most common side effects reported by patients taking fingolimod include headaches, flu-like symptoms, back pain, and diarrhea. Many patients also experience elevations in liver enzymes, which are usually detected through routine blood tests and don't cause noticeable symptoms. Other frequent issues include cough and sinusitis due to the drug's effect on the immune system. While these are common, they are usually manageable. However, any new or worsening symptom should be discussed with your neurologist to ensure it isn't a sign of a more serious complication.
There is no known direct chemical interaction between fingolimod and alcohol that would make moderate drinking strictly prohibited. However, both fingolimod and alcohol are processed by the liver and can cause liver stress or injury. Doctors generally recommend limiting alcohol consumption to avoid putting extra strain on the liver, especially since you will be undergoing regular liver function tests while on this medication. Excessive drinking could also mask some of the neurological side effects of the drug. Always consult your healthcare provider about what level of alcohol consumption is safe for your specific health profile.
Fingolimod is not considered safe during pregnancy and may cause significant harm or birth defects to an unborn baby. Women of childbearing age must have a negative pregnancy test before starting the drug and must use effective contraception during treatment. Because fingolimod stays in the body for a long time, you must continue using birth control for at least two months after your last dose. If you are planning to become pregnant, you should discuss a 'washout' period with your doctor. If you become pregnant while taking it, notify your healthcare provider immediately to discuss the risks and stop the medication.
Fingolimod begins to affect your immune system, specifically your lymphocyte count, within hours of the first dose. However, the full clinical benefits in terms of reducing MS relapses may not be apparent for several weeks or even months. It takes about one to two months of daily dosing for the drug to reach a 'steady state' in your bloodstream. Most clinical trials measured the effectiveness of the drug over a period of one to two years. It is important to continue taking the medication daily as prescribed, even if you do not feel an immediate change in your symptoms.
You should never stop taking fingolimod suddenly without your doctor's supervision. Stopping the medication can lead to a 'rebound' effect, where your MS symptoms return and may become significantly worse than they were before you started treatment. This severe worsening usually occurs within 3 to 6 months after stopping the drug. If you must stop fingolimod for medical reasons, your neurologist will need to monitor you very closely with MRI scans and clinical exams. They may also want to start you on a different MS therapy quickly to prevent a relapse.
If you miss a dose of fingolimod, do not take an extra dose to catch up. Instead, call your doctor immediately for instructions. Missing even a single dose can be serious because of the way the drug affects your heart rate. If you miss a dose during the first two weeks of treatment, you will likely need to repeat the 6-hour heart monitoring protocol in a clinic when you restart. The same applies if you miss more than 7 days of treatment later on. Consistency is vital for both the safety and the effectiveness of this medication.
Weight gain is not a commonly reported side effect of fingolimod in clinical trials. Most patients maintain a stable weight while on the medication. If you experience sudden or significant weight gain, it may be due to other factors, such as reduced mobility during an MS relapse, the use of corticosteroids to treat relapses, or other underlying health conditions. If you are concerned about weight changes, discuss them with your healthcare provider to determine the cause. They can help you manage your weight through diet, exercise, or adjustments to other medications.
Fingolimod can interact with several other medications, so it is crucial to provide your doctor with a full list of everything you take. It is particularly dangerous to take it with drugs that affect heart rhythm (antiarrhythmics) or other drugs that slow the heart rate, like beta-blockers. Combining it with other immunosuppressants can also increase your risk of severe infections. Some antibiotics and antifungal medications can also change the levels of fingolimod in your blood. Your doctor will carefully review your medications to ensure there are no dangerous interactions before starting your MS therapy.
Yes, fingolimod is available as a generic medication in many countries, including the United States. The FDA approved the first generic versions of Gilenya (fingolimod 0.5 mg capsules) in 2019. Generic fingolimod is required to have the same active ingredient, strength, dosage form, and route of administration as the brand-name version. It must also prove 'bioequivalence,' meaning it works the same way in the body. Choosing a generic can significantly reduce the cost of MS treatment for many patients and insurance providers.